YELLOW FEVER VIRUS Recombinant Protein

RECOMBINANT YELLOW FEVER VIRUS NS1 PROTEIN

Cat. Num. AAA50542

• Applications: ELISA
• Purity: >95% by SDS PAGE analysis
• Synonyms: YELLOW FEVER VIRUS; N/A; RECOMBINANT YELLOW FEVER VIRUS NS1 PROTEIN; YELLOW FEVER VIRUS recombinant protein

• Purity/Purification: >95% by SDS PAGE analysis
• Form/Format: Purified recombinant protein - liquid
• Concentration: Approximate Protein Concentration: Current, batch-specific concentration 0.513 mg/mL (varies by lot)

• Applicable Applications for YELLOW FEVER VIRUS recombinant protein: ELISA
• Source: HEK-293
• Preparation: Recombinant yellow fever virus NS1 protein, sequence strain 17D, expressed in 293 human cells
• Buffer Solution: Dulbecco's phosphate buffered saline
• Target Species: Viral
• Preservative Stabilizers: None Present
• Dry Ice Shipment: Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
• Preparation and Storage: Ships on Dry Ice.; Store at -70°C. Storage in frost free freezers is not recommended. This product should be stored undiluted. Avoid freezeing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

Related Product Information for YELLOW FEVER VIRUS recombinant protein

Recombinant yellow fever virus NS1 protein is produced as a hexamer in the human 293 cell line. This product has been purified and retains its native folding state and post-translational modifications providing optimal antigenicity. Research indicates that the hexamer is the biologically active form of the NS1 antigen and therefore involved in the pathogenesis of yellow fever virus (YFV). Yellow fever virus belongs to the Flaviviridae family and like closely related viruses, such as West Nile virus, is an abovirus utilizing various mosquito species as vectors. YFV appears to be restricted naturally to human and other primates but can be experimentally induced in other mammalian species. In recent years an increasing number cases of YFV infection have been reported. Originating in Africa, YFV has been introduced to tropical regions of South America and periodic outbreaks have historically occurred in both Europe and North America. According to the World Health Organization (WHO), it has been estimated that approximately 200,000 people contract YFV annually with around 30,000 cases resulting in fatality, the majority of these on the African continent.This product may be used in research to investigate vaccine development (Bonaldo, M.C. et al. 2014) or in research into the development of assays to detect YFV infection (Ding, X.X,et al. 2014).